

Newsletter from Emotra AB (publ)
Göteborg, March 16, 2016

A quick update – EDOR™ in the spotlight in Madrid

On March 12–15, Emotra participated in the European Psychiatric Association’s international meeting, which was held in Madrid, Spain. The interest and commitment is greater than ever now that we have completed the first stage of our large, multi-centre clinical study, EUDOR-A. More than 1,540 patients have been tested with EDOR™ since we started this study in the autumn of 2014.

EDOR™ was in the spotlight on a number of occasions at one of the year’s most important international psychiatric conventions, the *24th European Congress of Psychiatry, Madrid, Spain, 12–15 March, 2016*. At a specially arranged seminar where the future of suicide prevention was discussed, Emotra’s scientific advisor, Professor Marco Sarchiapone from Molise, Italy, held a presentation of EDOR™ and our ongoing, international clinical multi-centre study, EUDOR-A. This seminar was held in the largest auditorium and drew a very large audience. The seminar was led by two leading researchers, Philippe Courtet from Montpellier, France and Vladimir Carli from the Karolinska Institute, Stockholm, Sweden. Both of these researchers are involved in Emotra’s multi-centre study, EUDOR-A. Courtet is the manager of one of our clinical teams, while Carli is one of the researchers in charge of compiling and processing the results.

At a special workshop, *Suicide Risk Evaluation: From Research to Clinical Practice*, which was led by Professor Danuta Wasserman of the Karolinska Institute and Professor Marco Sarchiapone, Dr Lars-Håkan Thorell, the inventor of EDOR and Emotra’s Head of Research, and Professor Marco Sarchiapone each held a presentation about EDOR™. Thorell presented the research behind the theory of hyporeactivity’s significance for the risk of suicide, while Sarchiapone held another presentation about how the method works and how our effort to prove the method’s effectiveness and reliability has been organised.

Despite the fact that seven other workshops were going on at the same time, there were not enough seats to fit everyone who wanted to listen to Thorell and Sarchiapone. Some of the audience had to stand along the walls. We cannot draw any other conclusion than that interest in EDOR™ continues to grow.

We also arranged a special conference for the clinics that have participated in EUDOR-A. We invited a number of specialist children’s psychiatry clinics to this conference as well. Emotra was given clear indications of their interest in participating in our envisioned multi-centre study on children and young people, for which Emotra hopes to receive financial support through the EU’s Horizon 2020 program.

Last week Emotra announced the completion of the testing phase of the ongoing clinical multi-centre study, EUDOR-A. More than 1,540 patients have been tested and analysed. In the second stage of our study, the patients will be monitored and checked during a 12-month period after testing. This stage of our study will be finalized on March 10, 2017.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company’s method, EDOR™, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient’s response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.



All of this clinical patient data is now being compiled in Rome into a *clinical database*. At the same time, and without knowledge of the data in the clinical database, all of the test results are being compiled in an *EDOR™ Test database* in Linköping. These two databases will then be merged into a single, large *BASELINE DATABASE*. This work will enable us to study the relationship between hyporeactivity and previous suicide attempts, but also study the factors which are fundamental for theories of the reasons why some people commit suicide. The data analysis from the first stage of our study will result in a “Baseline publication”.

For further information, please contact: Claes Holmberg, CEO. Telephone: +46 708 25 45 47, E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR™, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se